Table 2. Association of expression of cytoskeleton proteins fascin-1, ezrin and paxillin and clinicopathological variables.
| Fascin-1, no. (%) | Ezrin, no. (%) | Paxillin, no. (%) | ||||||||||
| Clinicopathological variables | Negative | Low | High | P | Negative | Low | High | P | Negative | Low | High | P |
| Median age | ||||||||||||
| <59 years | 11(10.3) | 30(28.0) | 66(61.7) | 0.281* | 13(12.1) | 45(42.1) | 49(45.8) | <0.001 * | 12(11.2) | 25(23.4) | 70(65.4) | 0.532* |
| ≥59 years | 7(6.4) | 24(22.0) | 78(71.6) | 8(7.3) | 21(19.3) | 80(73.4) | 10(9.2) | 20(18.3) | 79(72.5) | |||
| Gender | ||||||||||||
| Female | 3(13.0) | 4(17.4) | 16(69.6) | 0.518* | 4(17.4) | 6(26.1) | 13(56.5) | 0.412* | 4(17.4) | 3(13.0) | 16(69.6) | 0.355** |
| Male | 15(7.8) | 50(25.9) | 128(66.3) | 17(8.8) | 60(31.1) | 116(60.1) | 18(9.3) | 42(21.8) | 133(68.9) | |||
| Primary sites | ||||||||||||
| Glottic | 13(11.2) | 42(36.2) | 61(52.6) | <0.001** | 14(12.1) | 38(32.8) | 64(55.1) | 0.380** | 16(13.8) | 22(19.0) | 78(67.2) | 0.310** |
| Supraglottic | 5(5.2) | 12(12.5) | 79(82.3) | 7(7.3) | 28(29.2) | 61(63.5) | 6(6.2) | 23(24.0) | 67(69.8) | |||
| Subglottic | 0(0.0) | 0(0.0) | 4(100.0) | 0(0.0) | 0(0.0) | 4(100.0) | 0(0.0) | 0(0.0) | 4(100.0) | |||
| Histologic differentiation | ||||||||||||
| Well | 11(13.1) | 38(45.2) | 35(41.7) | <0.001** | 15(17.9) | 38(45.2) | 31(36.9) | <0.001** | 16(19.0) | 31(36.9) | 37(44.1) | <0.001** |
| Moderate | 5(5.6) | 12(13.5) | 72(80.9) | 4(4.5) | 20(22.5) | 65(73.0) | 4(4.5) | 8(9.0) | 77(86.5) | |||
| Poor | 2(4.7) | 4(9.3) | 37(86.0) | 2(4.7) | 8(18.6) | 33(76.7) | 2(4.7) | 6(14.1) | 35(81.4) | |||
| Primary tumor | ||||||||||||
| T1+ T2 | 11(8.7) | 41(32.6) | 74(58.7) | 0.007 * | 14(11.1) | 44(34.9) | 68(54.0) | 0.125* | 14(11.1) | 30(23.8) | 82(65.1) | 0.332* |
| T3+ T4 | 7(7.8) | 13(14.4) | 70(77.8) | 7(7.8) | 22(24.4) | 61(67.8) | 8(8.9) | 15(16.7) | 67(74.4) | |||
| Cervical lymph node metastasis | ||||||||||||
| N0 | 17(10.5) | 46(28.6) | 98(60.9) | 0.006 * | 20(12.4) | 54(33.5) | 87(54.1) | 0.007 * | 20(12.4) | 38(23.6) | 103(64.0) | 0.021 * |
| N+ | 1(1.8) | 8(14.6) | 46(83.6) | 1(1.8) | 12(21.8) | 42(76.4) | 2(3.6) | 7(12.7) | 46(83.6) | |||
| Distant metastasis | ||||||||||||
| M0 | 18(8.5) | 54(25.6) | 139(65.9) | 0.566** | 21(10.0) | 65(30.8) | 125(59.2) | 0.806** | 22(10.4) | 45(21.3) | 144(68.2) | 0.758** |
| M1 | 0(0.0) | 0(0.0) | 5(100.0) | 0(0.0) | 1(20.0) | 4(80.0) | 0(0.0) | 0(0.0) | 5(100.0) | |||
| Clinical stage | ||||||||||||
| I+ II | 10(9.6) | 36(34.6) | 58(55.8) | 0.003 * | 13(12.5) | 37(35.6) | 54(51.9) | 0.071* | 14(13.5) | 27(26.0) | 63(60.6) | 0.035 * |
| III+ IV | 8(7.1) | 18(16.1) | 86(76.8) | 8(7.1) | 29(25.9) | 75(67.0) | 8(7.1) | 18(16.1) | 86(76.8) | |||
| Smoking status | ||||||||||||
| No | 12(14.3) | 23(27.4) | 49(58.3) | 0.023 * | 7(8.3) | 35(41.7) | 42(50.0) | 0.018 * | 9(10.7) | 23(27.4) | 52(61.9) | 0.145* |
| Yes | 6(4.5) | 31(23.5) | 95(72.0) | 14(10.6) | 31(23.5) | 87(65.9) | 13(9.8) | 22(16.7) | 97(73.5) | |||
*
Pearson chi-square, ** Fisher's Exact Test.